Efficacy and Safety of Pembrolizumab plus Axitinib combination for metastatic Renal Cell Carcinoma (mRCC) in a Real-World Scenario: data from the prospective ProPAXI study.-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and Safety of Pembrolizumab plus Axitinib combination for metastatic Renal Cell Carcinoma (mRCC) in a Real-World Scenario: data from the prospective ProPAXI study.

Published:2024-09 Issue: Volume: Page:102225
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Guida Annalisa,Gili Alessio,Mosillo Claudia,Maruzzo Marco,Lai Eleonora,Pierantoni Francesco,Bimbatti Davide,Basso Umberto,Fornarini Giuseppe,Rebuzzi Sara Elena,Calabrò Fabio,Cerbone Linda,Caserta Claudia,Sirgiovanni Grazia,Serafin Debora,Caffo Orazio,Scagliarini Sarah,Bracarda Sergio

Publisher

Elsevier BV

Reference20 articles.

1. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018;Ferlay;Eur J Cancer,2018

2. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial;Albiges;ESMO Open,2020

3. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma;Choueiri;N Engl J Med,2021

4. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma;Motzer;N Engl J Med,2021

5. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma;Rini;N Engl J Med,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP